EGFR and non-small cell lung carcinoma: Since FDA’s first approval of the cobas® EGFR CE-IVD Mutation Test (Roche Molecular Systems, Inc., Pleasanton, CA, USA) in 2016, as a companion diagnostic for osimertinib [15], another liquid biopsy test, the Guardant360 CDx (Guardant Health, Inc., Redwood City, CA, USA), has been recently verified by FDA for EGFR mutant NSCLC patients who may benefit from treatment with osimertinib [16,17].